Sohn Seo Young, Kim Yun Jin, Cho Sungsoo, Cho Sung Woo
Division of Endocrinology and Metabolism, Department of Internal Medicine, Myongji Hospital, Hanyang University College of Medicine, Goyang, Republic of Korea.
Biostatistics Lab, Department of Medicine, College of Medicine, Medical Research Collaborating Center, Hanyang University, Seoul, Republic of Korea.
Am J Cardiovasc Drugs. 2025 May;25(3):419-425. doi: 10.1007/s40256-024-00717-6. Epub 2025 Jan 11.
Amiodarone is an effective anti-arrhythmic drug; however, it is frequently associated with thyroid dysfunction. The aim of this study was to investigate the incidence and risk factor of amiodarone-induced dysfunction in an iodine-sufficient area.
This retrospective cohort study included 27,023 consecutive patients treated with amiodarone for arrhythmia, using the Korean National Health Insurance database. A Cox regression analysis was performed to determine independent risk factors for amiodarone-induced thyroid dysfunction.
During a mean follow-up period of 6.4 years, 1326 (4.9%) patients developed thyrotoxicosis and 3121 (11.5%) developed hypothyroidism. The incidence rate of amiodarone-induced thyrotoxicosis (AIT) and amiodarone-induced hypothyroidism (AIH) was 6.92 and 17.1 per 1000 person-years, respectively. In the multivariate analysis, chronic kidney disease (CKD) [hazard ratio (HR) 1.46, 95% confidence interval (CI) 1.06-1.99], and Hashimoto's thyroiditis (HR 2.00, 95% CI 1.31-3.07) were associated with AIT, while female sex (HR 1.22, 95% CI 1.14-1.32), diabetes (HR 1.14, 95% CI 1.06-1.24), CKD (HR 1.18, 95% CI 1.05-1.34), and Hashimoto's thyroiditis (HR 2.26, 95% CI 1.66-3.09) were associated with AIH.
The incidence of AIH was higher compared with AIT in an area with sufficient iodine intake. Several potential risk factors for AIT and AIH were identified. When amiodarone treatment is considered for patients, particularly those at a high risk of thyroid dysfunction, it is warranted to perform regular thyroid function assessments.
胺碘酮是一种有效的抗心律失常药物;然而,它常与甲状腺功能障碍有关。本研究的目的是调查碘充足地区胺碘酮所致功能障碍的发生率和危险因素。
这项回顾性队列研究纳入了韩国国民健康保险数据库中连续27023例接受胺碘酮治疗心律失常的患者。进行Cox回归分析以确定胺碘酮所致甲状腺功能障碍的独立危险因素。
在平均6.4年的随访期内,1326例(4.9%)患者发生甲状腺毒症,3121例(11.5%)患者发生甲状腺功能减退。胺碘酮所致甲状腺毒症(AIT)和胺碘酮所致甲状腺功能减退(AIH)的发病率分别为每1000人年6.92例和17.1例。多因素分析中,慢性肾脏病(CKD)[风险比(HR)1.46,95%置信区间(CI)1.06 - 1.99]和桥本甲状腺炎(HR 2.00,95%CI 1.31 - 3.07)与AIT相关,而女性(HR 1.22,95%CI 1.14 - 1.32)、糖尿病(HR 1.14,95%CI 1.06 - 1.24)、CKD(HR 1.18,95%CI 1.05 - 1.34)和桥本甲状腺炎(HR 2.26,95%CI 1.66 - 3.09)与AIH相关。
在碘摄入充足的地区,AIH的发病率高于AIT。确定了AIT和AIH的几个潜在危险因素。当考虑对患者进行胺碘酮治疗时,尤其是那些甲状腺功能障碍风险高的患者,有必要定期进行甲状腺功能评估。